ATLANTA, July 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a
biomaterials and biosurgical device company, today announced that it has
established a direct sales force through its European subsidiary, CryoLife
Europa, Ltd., to service the German medical market. Headquartered in the
biotechnology cluster of Baden-Wuerttemberg in Freiburg, the German team is
CryoLife's second direct sales force outside of the U.S. CryoLife also sells
direct in the United Kingdom.
"We are very excited about the potential for growth in the German market,"
said Steven G. Anderson, CryoLife president and chief executive officer.
"While we work with distributors throughout Europe, CryoLife Europa decided to
go direct in Germany to capitalize on the strong interest in our products
there. We believe that by having our own sales channel in Germany, we can
focus our selling efforts, strengthen our market presence and more readily
launch new products."
CryoLife's German sales force will include three sales representatives and
a sales manager. The first two sales representatives will cover Southern
Germany, mainly Bavaria and Baden-Wuerttemberg, and Northeast Germany, which
includes Berlin, Hamburg and Leipzig. Plans call for the addition of a third
sales representative to cover the Western German territory by the end of 2007.
The team will initially concentrate on sales of CryoLife's BioGlue(R), a
surgical adhesive, and the distribution of allograft tissues.
The CryoLife sales office in Germany can be contacted by calling
+49 (0) 761-216886-0, by fax +49 (0) 761 216886-10 or by emailing
Prior to the creation of a direct sales operation, CryoLife Europa, Ltd.
distributed CryoLife products in Germany through Krauth Medical KG (GmbH &
About CryoLife Europa, Ltd.
Headquartered in Guildford, Surrey, United Kingdom, CryoLife Europa, Ltd.,
established in 1999, directs the distribution of CryoLife products and tissues
throughout Europe, the Middle East and Africa (EMEA).
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and
distribution of implantable living human tissues for use in cardiac and
vascular surgeries throughout the United States and Canada. The Company's
BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and
staples for use in adult patients in open surgical repair of large vessels.
BioGlue is also CE marked in the European Community and approved in Canada and
Australia for use in soft tissue repair. The Company also distributes the
CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100
vascular graft, which are CE marked for distribution within the European
For additional information about the company, visit CryoLife's Web site:
SOURCE CryoLife, Inc.
D. Ashley Lee,
Executive Vice President, Chief Operating
Officer and Chief Financial Officer of CryoLife, Inc. +
Katie Brazel of Fleishman-Hillard,
Web site: http://www.cryolife.com